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Abstract
Objectives To investigate the added value of computer-aided
diagnosis (CAD) on the diagnostic accuracy of PIRADS
reporting and the assessment of cancer aggressiveness.
Methods Multi-parametric MRI and histopathological out-
come of MR-guided biopsies of a consecutive set of 130 pa-
tients were included. All cases were prospectively PIRADS
reported and the reported lesions underwent CAD analysis.
Logistic regression combined the CAD prediction and radiol-
ogist PIRADS score into a combination score. Receiver-
operating characteristic (ROC) analysis and Spearman’s cor-
relation coefficient were used to assess the diagnostic accura-
cy and correlation to cancer grade. Evaluation was performed
for discriminating benign lesions from cancer and for discrim-
inating indolent from aggressive lesions.
Results In total 141 lesions (107 patients) were included for
final analysis. The area-under-the-ROC-curve of the combi-
nation score was higher than for the PIRADS score of the
radiologist (benign vs. cancer, 0.88 vs. 0.81, p=0.013 and
indolent vs. aggressive, 0.88 vs. 0.78, p<0.01). The combina-
tion score correlated significantly stronger with cancer grade
(0.69, p=0.0014) than the individual CAD system or radiolo-
gist (0.54 and 0.58).
Conclusions Combining CAD prediction and PIRADS into a
combination score has the potential to improve diagnostic
accuracy. Furthermore, such a combination score has a strong
correlation with cancer grade.
Key Points
• Computer-aided diagnosis helps radiologists discriminate
benign findings from cancer in prostate MRI.
• Combining PIRADS and computer-aided diagnosis im-
proves differentiation between indolent and aggressive
cancer.
• Adding computer-aided diagnosis to PIRADS increases the
correlation coefficient with respect to cancer grade.
Keywords Magnetic resonance imaging . Prostate cancer .
Computer-aided diagnosis . Observer study . Diagnostic
performance
Introduction
Multi-parametric magnetic resonance imaging (mpMRI) is
emerging as an important modality in prostate cancer diagno-
sis [1–3]. Several studies have shown that in patients with
initial negative trans-rectal ultrasound-guided biopsies
(TRUSGB) and persistently elevated prostate-specific antigen
(PSA) expert readers using mpMRI find cancer in 38–59 % of
the cases [4, 5]. Furthermore, it has been shown that mpMRI
correctly upgrades TRUSGB-detected cancers in up to 30 %
of cases [6]. Several other studies found that the negative
predictive value of mpMRI is high enough to avoid TRUS
GB in 30–50 % of men with persistently elevated PSA [7,
8]. However, one of the main limitations for broader accep-
tance of mpMRI is the lack of required expertise, especially in
the acquisition and interpretation of the MR images [1, 9, 10].
In order to improve the acquisition and interpretation of
mpMRI, the European Society for Urogenital Radiology
(ESUR) established initial guidelines for acquisition and stan-
dardized interpretation of mpMRI (PIRADS) [1]. These
guidelines have been evaluated by several groups, for
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detection of cancer both prior to biopsy [8, 11] and after initial
negative TRUSGB [12–15]. There are, however, still two ma-
jor issues in current prostate MRI: determining which cancers
need treatment (assessment of aggression) and the large
amount of false positives resulting in unnecessary biopsies.
Computer-aided diagnosis (CAD) might be able to address
these problems.
The purpose of this study is twofold. One is to provide a
clinical investigation of the effect of CAD [16] on the diag-
nostic accuracy of prostate mpMRI reporting via independent
combination of PIRADS scores and CAD prediction into a
radiologist/CAD combination score. The performance of this
combination score is evaluated in a comparatively large cohort
of patients withMR-guidedMR-biopsy histopathological out-
come as reference standard. Secondly, we investigate the abil-
ity of CAD to estimate prostate cancer aggressiveness.
Materials and methods
Patient data
An institutional review board (IRB) waiver applies to this study
as it uses anonymized imaging data and MR-guided biopsy
results obtained through regular clinical care. In total 130 con-
secutive patients from 1 January to 1 September 2013 who
received both an mpMRI and a subsequent MR-guided MR-
biopsy at our institution were included. The inclusion criteria
for the detectionmpMRIwere an initial negative TRUSGB and
persistently elevated PSA (consistently above 4 ng/mL).
Multi-parametric MRIs were acquired according to the
ESUR guidelines and included T2-weighted imaging in three
orthogonal directions, diffusion-weighted imaging and dy-
namic contrast-enhanced imaging. All MRIs were performed
at a Siemens 3 T MRI scanner (TRIOTIM or Skyra) without
an endo-rectal coil. Full acquisition details are presented in
Table 1.
Each mpMRI was regularly, prospectively read by one ra-
diologist out of a group of seven radiologists who reported
prostate MRI in our clinic. Experience levels of the reporting
radiologist ranged from moderately experienced (2 years) to
very experienced (J.B., 20 years). Details on the amount of
cases read by each radiologist are presented in Table 2. The
ESUR prostate imaging reporting and data system (PIRADS)
classification was used to assign a five-point PIRADS score to
one or more lesions.
Each MR study was reported using a dedicated prostate
MR workstation that allowed radiologists to indicate one or
more areas of suspicion with a sphere enclosing the lesions. If
no suspicious areas could be identified, a location was marked
which was deemed normal/benign and assigned a PIRADS
score of 1 or 2. This is performed in routine clinical care for
accountability, to ensure that each case has been read and Ta
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reported. Typically, PIRADS 1 or 2 lesions do not get
biopsied. Sometimes a PIRADS 2 lesion was also biopsied,
when a PIRADS 3 or higher lesion was also identified and the
patient was thus already scheduled for MR-guided MR biop-
sy. The locations and scores were automatically recorded in a
database.
MR-guided biopsies were performed by medical experts
with multiple years of experience in MR-guided prostate bi-
opsies. At the start of the biopsy procedure a T2-weighted
volume and an ADC map were acquired according to the
prostate cancer detection protocol (Table 1). These sequences
were used to relocate the lesions in the prior detection MRI.
After lesions have been identified, a needle guide is inserted
transrectally. Consecutive sagittal and transversal MRIs are
made during repositioning of the needle guide to assess
whether the correct position has been reached. Once the cor-
rect position has been reached a biopsy needle is inserted and a
biopsy taken. To verify the biopsy location, sagittal and trans-
versal images were made with the needle in situ. Subsequent-
ly, biopsies were histopathologically processed, inspected and
graded by an experienced uropathologist (17 years of experi-
ence in prostate pathology).
Computer-aided diagnosis system
The computer-aided diagnosis system evaluated in this paper
was previously presented in [16]. First, the system computes
quantitative voxel features, which were designed to capture
characteristics described by the PIRADS guidelines. A full
feature listing can be found in Table 3. These voxel features
are then fed to a random forest classifier trained to determine a
continuous likelihood score for each voxel to identify cancer,
resulting in a likelihood image. Subsequently, in a second
stage, the system used the centre of the sphere indicated by
the radiologist as a starting point for lesion segmentation,
which is performed on the pre-computed likelihood image.
After lesion segmentation histogram statistics are calculated
on the voxel features within the lesion (e.g., percentiles, mean,
standard deviation). In addition, local contrast is calculated by
comparing the voxel feature values within the lesion to values
outside the lesion. Symmetry is calculated by comparing the
feature values within the lesion to the feature values at the
same relative position on the contra-lateral side of the prostate.
The statistical, local contrast and symmetry features are then
combined using a second random forest classifier trained to
predict cancer likelihood per lesion. The system is able to take
into account the zonal location of the lesion via the use of a
probabilistic segmentation of the prostate zones as one of its
features (Table 3). The construction of this probabilistic seg-
mentation is detailed in [17].
The CAD system was trained with independent, retrospec-
tive patient data (237 patients), which had no overlap with the
data set used in this study. The retrospective data was acquired
in a similar manner (same MRI protocol) as the evaluation
data and also hadMR-guided biopsy as the reference standard.
Combination of PIRADS score and computer-aided
diagnosis (CAD) likelihood
The use of the system as proposed in this paper is presented
schematically in Fig. 1. The initial identification of potential
suspicious regions was performed by the radiologist, after
which the radiologist and the CAD system gave independent
scores onwhether clinically significant cancer was present [1].
The radiologist did this by assigning a five-point PIRADS
score, while the CAD system assigned a continuous likelihood
score between 0 and 1.
The reported scores of the radiologists (PIRADS) and CAD
(likelihoods) were combined into a combination score via lo-
gistic regression, which is a technique to map multiple vari-
ables to one single, continuous outcome variable (between 0.0
and 1.0) in an independent manner. The regression model was
created with SPSS (version 20.0.01, Chicago, IL, USA). The
logistic regression was performed on the retrospective data
that was also used to train the CAD system to ensure no bias
would occur by training and testing on the same data. It was
thus independent of the evaluation data used in this paper.
Alternative methods of incorporating CAD results may be
used in clinical workflow, such as asking a second radiologist
to make a final decision based on the two scores, but these
were not investigated in this paper.
Statistical evaluation
Radiologist-identified lesions were categorized into either be-
nign or cancer based on the MR-guided MR biopsy outcome.
Cancerous lesions were further subdivided into low-grade,
intermediate-grade or high-grade cancer based on the MR-
guided biopsy Gleason scores, similar to Vos et al. [18] and
Hambrock et al. [19]. Our high-sensitivity MR-guided biopsy
strategy has been shown to have a concordance of 95 % with
prostatectomy Gleason grade [20].
Table 2 Overview of radiologist reading cases in the study cohort,
including amount of cases read (out of 107 included studies) and years
of experience
Reader Years of experience Cases read
J.B. 20 25
J.F. 12 14
P.Z. 8 16
S.J. 3 20
M. vd. L 2 22
R.M. 2 5
J.H. 2 5
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We used two different settings for evaluation in this study:
either benign versus cancerous or indolent versus aggressive
lesions. In the latter case the benign and low-grade lesions are
considered indolent and intermediate- and high-grade lesions are
considered aggressive. These settings are summarized in Table 4.
TheCAD system and logistic regressionmodel were constructed
separately for each setting using the retrospective data.
The statistical evaluation consisted of three parts. First, we
investigated the hypothesized increase in predictive power of
the combination score over the radiologist PIRADS score
alone using the likelihood ratio test on the logistic regression
models.
Second, the diagnostic performance of the CAD system,
the radiologist PIRADS score and the combination score was
evaluated using receiver-operating characteristic (ROC) anal-
ysis for both evaluation strategies. The significance of im-
provement for area under the ROC curve, and different
sensitivity-specificity pairs at the different PIRADS thresh-
olds, was tested using bootstrapping. A total of 10,000 boot-
strap samples was used to obtain the 95 % confidence inter-
vals (CIs). Bootstrapping was stratified according to patient to
circumvent bias introduced by multiple lesions per patient.
To assess the effect of the zonal location of the lesions on
the performance of the radiologist, the CAD system and the
combination score the dataset was split into two sets, one set
containing only central gland lesions and one set only contain-
ing peripheral zone lesions.
The effect of observer experience on the performance of
the combination score was also assessed. The dataset was split
into two groups, one containing the cases reported by the
experienced radiologists (more than 5 years) and one contain-
ing the cases reported by the less experienced radiologists
(less than 5 years, but more than 2 years).
Third, we correlated radiologist PIRADS, CAD score and
the combined score to cancer grade. As cancer grade is an
ordinal variable, Spearman’s rank correlation coefficient was
used. The significance of differences in correlation
Table 4 Mapping of Gleason scores to cancer grade
Gleason scores Grade Category
None Benign Indolent
3+3 or lower,
no 4 or 5 component
Low-grade Indolent
2+4, 3+4, 2+5 Intermediate-grade Aggressive
3+5, any cancer with a
major 4 or 5 component
High-grade Aggressive
Fig. 1 Suggested workflow for the proposed computer-aided diagnosis
(CAD) system. The biopsy decision can be made by the radiologist,
another attending clinician or by using the combination score to indepen-
dently combine the PIRADS score and the CAD likelihood
Table 3 Descriptions of the voxel features used in the computer-aided diagnosis system
Name Type Description
T2W Intensity T2-weighted voxel grey value, related to voxel T2
ADC Intensity Apparent diffusion coefficient, measure for cellular density
b800 Intensity High b-value image, areas with low diffusivity appear bright
T2-map Intensity Calculated T2-map based on proton density and transversal T2W image [17]
x-pos Anatomical Relative cumulative position within the prostate mask between 0 and 1 in the x-direction
y-pos Anatomical Relative cumulative position within the prostate mask between 0 and 1 in the y-direction
z-pos Anatomical Relative cumulative position within the prostate mask between 0 and 1 in the z-direction
Distance Anatomical Relative distance to the prostate boundary between 0 and 1
PZ Likelihood Anatomical likelihood of being a peripheral zone voxel between 0 and 1 [17]
Ktrans Pharmacokinetic Pharmacokinetic parameter, related to vessel permeability
kep Pharmacokinetic Pharmacokinetic parameter, related to permeability and extracellular volume
tau Pharmacokinetic Dynamic parameter, related to the time-to-peak of contrast agent concentration
LateWash Pharmacokinetic Dynamic parameter, related to the washout of contrast agent
Gaussian texture bank Texture Calculate multi-scale Gaussian derivatives on the T2W image
ADC Spatial filter Multi-scale focal lesion detection using the Li spatial filter [27] on ADC map
Ktrans Spatial filter Multi-scale focal lesion detection using the Li spatial filter [27] on Ktrans map
LateWash Spatial filter Multi-scale focal lesion detection using the Li spatial filter [27] on LateWash map
tau Spatial filter Multi-scale focal lesion detection using the Li spatial filter [27] on tau map
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coefficients was tested using Steiger’s z-test for dependent
correlation coefficients [21]. For all significance tests a p-
value threshold of 0.05 was chosen. SPSS (SPSS, version
20.0.01) and in-house developed tools for bootstrapping were
used for all statistical analysis.
Results
Patient data
Of the initially included 130 patients, 23 were excluded, 18
due to previous treatment for prostate cancer, two for failed
diffusion-weighted imaging, two because they did not under-
go dynamic contrast-enhanced imaging and one patient be-
cause no biopsy was taken during the biopsy session. The
107 included patients had a median age and PSA level of
66 years (range 48–83) and 13 ng/mL (range 1–56),
respectively, which is similar to other studies using patient
data with the same inclusion criteria (initial negative TRUS
GB and persistently elevated PSA) [12–15]. Further details
are summarized in Fig. 2 and Table 5.
In total 141 suspicious regions were identified in these pa-
tients. All these regions were biopsied under MR-guidance. Of
these regions, 68 % were positive and 32 % were negative for
prostate cancer. The zonal distribution of the lesions was almost
equal, with 69 regions being located in the peripheral zone and
72 in the central gland. Gleason grades were 2+5 (1 %), 3+2
(2 %), 3+3 (27 %), 3+4 (38 %), 4+3 (13 %), 4+4 (5 %), 4+5
(10 %), 5+4 (3 %) and 5+5 (1 %). Further details about the
distribution of the lesion grades can be found in Table 5.
The effect of CAD on radiologist performance
First, the logistic regression procedure showed that including
the CAD system likelihood in addition to the radiologist PIRA
Table 5 Characteristics of patients and biopsy specimens for the
prospective cohort used to evaluate the potential added value of a
computer-aided diagnosis system for the assessment of prostate cancer.
For each group of lesions the numbers between brackets indicate the
number of lesions in the peripheral zone and the central gland,
respectively
Number of patients 107
PSA level, ng/ml, median (range) 13 (1–56)
Age, y, median (range) 66 (48–83)
Percentage of cancer per core, median (range) 50 (7–100)
Gleason score Grade No. of lesions Totals 141 (69/72)
Normal/Benign Normal/Benign 45 (28/17) No cancer 45 (28/17)
2+5 Intermediate 1 (0/1) Low 28 (10/18)
3+2 Low 2 (0/2) Intermediate 37 (16/21)
3+3 Low 26 (10/16) High 31 (15/16)
3+4 Intermediate 36 (16/20)
4+3 High 12 (7/5)
4+4 High 5 (2/3)
4+5 High 10 (4/6)
5+4 High 3 (2/1)
5+5 High 1 (0/1)
Fig. 2 STARD diagram of inclusion and exclusion criteria of the prospective patient cohort
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DS score resulted in a model with significantly improved pre-
dictive power (p<0.001, likelihood ratio test) for both evalu-
ation settings (benign vs. cancer and indolent vs. aggressive).
Using the obtained regression coefficients we created a
weighted combination score:
Combination score ¼ 4:739C þ 1:06P
for the benign versus cancer setting and
Combination score ¼ 3:886C þ 1:295P
for the indolent versus aggressive setting. C is the CAD sys-
tem likelihood (ranging from 0 to 1) and P is the radiologist
PIRADS score (ranging from 1 to 5). The regression models
are visually represented in Fig. 3.
The ROC analyses showed a significant increase (p<0.05)
in area under the ROC curve from 0.81 to 0.88 in the benign
versus cancer setting and from 0.78 to 0.87 in the indolent
versus aggressive setting when using the combination score
versus only PIRADS (Fig. 4a, b and Table 6). Furthermore, this
increase is not affected by the zonal location of the lesion under
investigation (Fig. 4c, d, e and f and Table 7). The ROC anal-
ysis also shows that radiologists and CAD have a comparable
diagnostic accuracy. Lastly, Table 6 also includes the increases
in sensitivity and specificity obtained at specific PIRADS
scores when using the combination score. For example, at
PIRADS 4without using CAD a sensitivity of 0.93 is attainable
at a specificity of 0.37 in the indolent versus aggressive setting.
However, when combining the PIRADS score with the CAD
score we obtain a significantly increased sensitivity of 0.98 at a
significantly increased specificity of 0.59 (p<0.05). Last, we
show that both less experienced and experienced readers can
improve their performance by using CAD. In the indolent ver-
sus aggressive evaluation setting both groups improve signifi-
cantly when using CAD with an increase in AUC from 0.76 to
0.85 for less experienced and from 0.78 to 0.87 for experienced
readers (Fig. 5, Table 8). In the benign versus cancer settings
both groups also improve, but only the less experienced readers
significantly (AUC from 0.79 to 0.89).
Correlation of likelihood and cancer grade
BothCAD likelihood and PIRADS score correlate significant-
ly with cancer grade, but the combination score shows the
strongest correlation. This is confirmed when assessing the
correlation coefficients. In the benign versus cancer setting,
correlation was 0.534, 0.582 and 0.684 for CAD, radiologist
and combination, respectively. In the indolent versus aggres-
sive setting the correlation coefficient was 0.536, 0.582 and
0.694 for CAD, radiologist and combination, respectively.
The increase in correlation when using the combination score
instead of just PIRADS or CADwas significant (p<0.01). The
ability of each of the three scores to predict aggressiveness is
visualized in Fig. 6 for both evaluation settings.
Fig. 3 Visual depictions of the regression models to generate the
combination score of the radiologist and the computer-aided diagnosis
(CAD) system: (a) shows the model for the benign vs. cancer setting, (b)
for the indolent vs. aggressive setting. The likelihood of cancer is indi-
cating by the colour coding and the contour labels and ranges from 0 to 1.
Green indicates low likelihood and red indicates high likelihood
Fig. 4 Receiver-operating characteristic (ROC) curve showing the
performance of the computer-aided diagnosis (CAD) system (orange)
and the radiologist/CAD-system combination (blue). The shaded areas
indicated the 95 % confidence intervals (CIs) as calculated using
bootstrapping. The radiologist performance is indicated with point for
the different PIRADS thresholds. The vertical error bars indicate the
95 % CI on the sensitivity and horizontal error bars indicated the 95 %
CI on the specificity as estimated by bootstrapping. a, c and e are the
results of the benign versus cancer evaluation setting, b, d and f are the
result of the indolent versus aggressive settings. a and b show the results
over all lesions, c and d only the peripheral zone lesions and e and f only
the central gland lesions
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Discussion
A recently developed CAD system for the computerized anal-
ysis of prostate MR was shown to have a similar diagnostic
accuracy to well trained prostate MR radiologists. When com-
bined with the PIRADS score into a combination score, diag-
nostic performance improved significantly. It is important to
note that the CAD system was used in a regular clinical prac-
tice setting on a large cohort. This provides further evidence of
the benefit of CAD in helping improve diagnostic accuracy.
The CAD system score showed a significant correlation
(0.54) with cancer grade similar to the PIRADS score (0.58).
A significantly higher correlation (0.69) was obtained by
using the combination score. This correlation coefficient is
the highest currently reported in literature [18, 22]. A notice-
able difference with other multivariate aggressiveness corre-
lation studies is that this study attains the correlation in a
setting with radiologist-indicated regions instead of pathology
pre-defined regions of interest, which is more similar to regu-
lar clinical practice.
Although the performance of both the radiologist and the
CAD system were similar, they provide complementary infor-
mation, as the combination score results in an improved ROC
curve (blue curve, Fig. 4a, b). In both evaluation settings (be-
nign vs. cancer and indolent vs. aggressive) the area under the
ROC curve increased significantly (0.81 to 0.88, p=0.013 and
0.78 to 0.87, p=0.001, respectively). If we compare these
results to those found in the literature, we observe similar
values for performance of readers with CAD; however, the
PIRADS performance is somewhat lower in our study (0.84
to 0.87 in [23], 0.85 to 0.91 in [24]). We believe these
differences to be caused by the difference in reading setting
and the fact that we used a substantially larger and more dif-
ficult cohort. Our study used prospective clinical reading,
whereas these previous studies used a retrospective batch
reading setting. Furthermore, previous studies were limited
to patients scheduled for radical prostatectomy, which differs
from the regular clinical population used in this study.
Furthermore, we showed that identifying clinically signif-
icant disease using CAD can improve both experienced and
less experienced readers (increase of 0.09 in AUC for both
groups). However, when discriminating any cancer from be-
nign lesions only less experienced readers improved signifi-
cantly, indicating that CAD might especially be helpful in
identifying clinically significant disease. Note that direct com-
parison between the performance of less experienced and ex-
perienced readers cannot be performed in this study as both
groups reported on different patients. However, we do not
expect results to change as both groups evaluated a sufficient-
ly large and similar subset of cases.
The added value of CAD did not seem to depend on the
zonal location of the lesions. Increase in performance when
using CAD was similar for both peripheral zone and central
gland lesions. The CAD system performed equally well on
peripheral zone and central gland lesions, indicating that it
has successfully learned how to take into account the zonal
characteristics of the lesions. CAD could possibly help shift
the biopsy threshold from PIRADS 3 to PIRADS 4, which
would lead to a significant reduction of MR-guided biopsies.
At a PIRADS threshold of 3, CAD significantly increased the
specificity in both evaluation settings (Table 1; 0.15 to 0.30,
p=0.020 and 0.09 to 0.26 p=0.023). At the PIRADS 4
Table 6 Sensitivity-specificity pairs and area under the receiver
operating characteristic (ROC) curve for the radiologist and the
computer-aided diagnosis (CAD)-radiologist combination including
95 % confidence intervals (CIs) and p-values determined by
bootstrapping. Significant p-values (p<0.05) are indicated in bold. The
first part of the table contains the results for the benign vs. cancer evalu-
ation setting whereas the second part of the table contains the results for
the indolent vs. aggressive evaluation setting
CAD+radiologist Radiologist
Benign vs. cancer Sensitivities, mean
(95 % CI)
p-value Specificities, mean
(95 % CI)
p-value Sensitivities, mean
(95 % CI)
Specificities, mean
(95 % CI)
PIRADS 2 1.0 (1.0–1.0) 1 0.25 (0.0–0.44) 0.008 1.0 (1.0–1.0) 0.12 (0.0–0. 27)
PIRADS 3 0.99 (0.99–1.0) 0.49 0.30 (0.17–0.45) 0.02 0.99 (0.98–1.0) 0.15 (0.04–0.28)
PIRADS 4 0.92 (0.84–0.98) 0.44 0.50 (0.26–0.72) 0.48 0.91 (0.81–0.97) 0.49 (0.30–0.67)
PIRADS 5 0.76 (0.61–0.88) 0.08 0.90 (0.77–0.98) 0.098 0.62 (0.38–0.79) 0.81 (0.67–0.92)
AUC 0.878 (0.824–0.928) 0.013 0.808 (0.728–0.880)
CAD+radiologist Radiologist
Indolent vs. aggressive Sensitivities, mean
(95 % CI)
p-value Specificities, mean
(95 % CI)
p-value Sensitivities, mean
(95 % CI)
Specificities, mean
(95 % CI)
PIRADS 2 1 (1–1) 1 0.259 (0.00–0.604) 0.023 1 (1–1) 0.094 (0.0–0.185)
PIRADS 3 0.99 (0.98–1.0) 0.51 0.259 (0.00–0.604) 0.023 0.997 (0.983–1.0) 0.094 (0.0–0.185)
PIRADS 4 0.98 (0.94–1.0) 0.029 0.585 (0.379–0.763) 0.013 0.934 (0.861–0.98) 0.366 (0.200–0.536)
PIRADS 5 0.82 (0.68–0.96) 0.09 0.78 (0.64–0.90) 0.105 0.731 (0.523–0.873) 0.707 (0.534–0.833)
AUC 0.874 (0.813–0.927) 0.001 0.779 (0.701–0.848)
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threshold a significant increase in sensitivity and specificity
was found (0.93 to 0.98, p=0.029, 0.37 to 0.59, p=0.013) in
the indolent versus aggressive setting. The latter indicates that
by using CAD and increasing the biopsy threshold from PIRA
Fig. 5 Receiver-operating characteristic (ROC) curve showing the
performance of the combined score vs. the radiologist alone with
respect to the level of experience. The shaded areas indicated the 95 %
confidence intervals (CIs) as calculated using bootstrapping. The
radiologist performance is indicated with point for the different PIRA
DS thresholds. The vertical error bars indicate the 95 % CIs on the
sensitivity and horizontal error bars indicated the 95 % CI on the
specificity as estimated by bootstrapping. a is the result of the benign
versus cancer evaluation setting, b is the result of the indolent vs.
aggressive settings
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DS 3 to 4 almost no loss in detection of aggressive lesions
(sensitivity 0.99 vs. 0.98) occurs, while a specificity improve-
ment is obtained (0.59 vs. 0.26), reducing unnecessary biop-
sies. Of course this has to be investigated further in future
clinical studies. One important aspect relevant to patient prog-
nosis was not assessed by the CAD system; the presence or
absence of extracapsular extension. Being able to identify this
aspect would further enhance the applicability of the CAD
system.
This study has some limitations. Firstly, MR-guided biopsy
has a 95% concordance with prostatectomy Gleason grade for
Gleason 4 and 5 components [20, 25] and has been shown to
be able to detect clinically significant cancer in men with
previous negative TRUS biopsies [26]. Although in general
concordance rates with prostatectomy Gleason grade are high,
they are not perfect. Thus, some of the cancers in our study
may be under- or overgraded. We expect the effect on our
results to be minimal, as this only effects the indolent versus
aggressive setting.
A second limitation is that each case in this study was read
by one of seven radiologists. We know diagnostic accuracy is
dependent on reader experience and thus our results depend
on the average reader experience of the group. All our readers
have had reasonable training and experience of at least 2 years
[8, 11].
Third, due to the single reader per case and the pro-
spective reading setting inter- and intraobserver variabil-
ity and false-negative rates could not be assessed. As
such, this study does not vacate the need for retrospec-
tive observer studies, in which these aspects could be
assessed, but provides a different, more clinically realis-
tic view on the added value of CAD. Furthermore, due to
our comparatively large number of cases we were still
able to show significantly improved diagnostic perfor-
mance when using CAD.
The proposed method of implementing CAD in clinical
practice (independent combination of PIRADS score and
CAD likelihood into a combination score) might not be
feasible, as radiologists or urologists will always have the
final say. Nevertheless, we choose to perform independent
combination to assess the potential observer-independent
effect of CAD. In future work, one could assess the most
optimal way for radiologists to incorporate CAD results in
their reports.
PIRADS 1 and 2 lesions were generally not biopsied and
therefore are only partially included in this study. This pre-
cludes assessment of the effect of the CAD system in those
lesions. However, this has little impact on the results of this
study. Of all seven biopsied PIRADS 2 lesions, none were
categorized as cancer. The negative predictive value of
PIRADS 1 and 2 scores is already so high that radiologist do
not need computer aid for these PIRADS scores. The literature
also confirms this assessment, with the studies by ThompsonTa
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et al. [8] and Pokorny et al. [11] reporting MRI sensitivities
and negative predictive values of 97 and 96.9 %, respectively.
The CAD system has most potential in more accurately dis-
criminating which PIRADS 3, 4 or 5 lesions require biopsy
and the results at these scores are not affected by the lack of
PIRADS 1 or 2 biopsies.
Last, the patient population in this study contained only
patients for whom initial PSA tests and TRUS biopsies were
inconclusive. As such, the results of this study cannot be di-
rectly translated to other patient groups (e.g., staging). How-
ever, due to the similar protocols for detection and staging
MRI we expect results to be comparable. Furthermore, with
prostate cancer guidelines in many countries now
recommending MRI if PSA/TRUS results are inconclusive,
we expect that the majority of prostate MRIs will be done
for detection purposes.
Fig. 6 Relationship between computer-aided diagnosis (CAD) system
likelihood and cancer grade presented by box-plots. One can observe a
positive correlation between cancer grade and CAD system likelihood. a
is the result of the benign vs. cancer evaluation setting, b is the result of
the indolent vs. aggressive settings
Eur Radiol (2015) 25:3187–3199 3197
Conclusions
In this paper the use of a CAD system in conjunction with the
radiologist to accurately characterize prostate lesions was in-
vestigated. Results showed that a significant increase in diag-
nostic performance can be achieved when combining the ra-
diologist PIRADS score and CAD system likelihood into a
combination score. Furthermore, a significant correlation be-
tween CAD likelihood and cancer grade exists; this increases
further when using the combination score.
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